UMIP-257 – Vanilloids Nanoparticles for Induction of Therapeutic Hypothermia

Problem: Neurological disorders caused by cardiac arrest, brain trauma,spinal cord injury, hemorrhagic stroke, and other acute conditions areconsidered a major medical concern. Therapeutic hypothermia (TH), a type oftarget temperature management, has emerged as a beneficial post-traumatictreatment for such medical conditions. The basis of this therapy lies inintentionally decreasing the body temperature a couple of degrees belowphysiological temperature, 36°C, to prevent a surge in neuronal cell death. THcan also positively impact cellular mechanisms, including decreasing/inhibitingfree radical generation, inflammation, and processes such as angiogenesis andapoptosis. To date, several preclinical studies have shownlong-term health improvement as a result of the application of moderatehypothermia to patients suffering from an ischemic or traumatic incident.However, to achieve true efficient hypothermia, thereare a series offactors that require better control. Those factors include the therapeuticwindow, optimal duration of cooling, and rewarming rate. Current medical practicessuch as the use of ice packs, cooling blankets, or the injection of cold salinesolutions lack the effectiveness to reach the target temperature at an adequatecooling speed. In addition, the external cooling techniques are associated withside effects, such as shivering, and require a cumbersome operation setup. Theintroduction of pharmacological agents that can induce targeted therapeutichypothermia has emerged as the state-of-the-art treatment to provideneuroprotection. However, the use of these agents, at the micro- andmeso-scales, is still associated with several drawbacks, such as the use ofhigh doses of the drugs/agents, the intravenous route of administration, andmultiple side effects associated with TH treatment. Vanilloids agents inparticular such as capsaicin and rinvanil have shown specific and effectiveneuroprotective effects against traumatic conditions; however, the continuousinfusion method of high dose of these drugs has been associated with issuessuch as hypotension and bradycardia. Technology: Researchers at the University of Miami have developed novelmethods of formulating vanilloid compounds into nanoparticles, allowing for efficientinduction of therapeutic hypothermia by nasal or oral administration at lowdoses, thus avoiding unwanted side effects. Peter Gutenberg pxg372@miami.edu 305-243-4604

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More